HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Antunes, M. J. Articles by Santos, L. P. Search for Related Content PubMed PubMed Citation Articles by Antunes, M. J. Articles by Santos, L. P.

The Annals of Thoracic Surgery, Vol 37, 387-392, Copyright © 1984 by The Society of Thoracic Surgeons

ARTICLES

Performance of glutaraldehyde-preserved porcine bioprosthesis as a mitral valve substitute in a young population group

MJ Antunes and LP Santos

Porcine bioprostheses were implanted in the mitral position in 289 patients. The mean age was 25.8 +/- 13.7 years. One hundred thirty-five patients (47%) were 20 years old or younger. Most patients had chronic rheumatic valvulitis (74%). Mitral regurgitation and mixed mitral valve disease were the dominant lesions. Hancock, Angell-Shiley, and Carpentier-Edwards prostheses were implanted in 84, 14, and 191 patients, respectively. There were 19 early and 64 late deaths. Mean follow-up was 5.04 +/- 1.03 patient-years. Fifty-eight patients (6.71% per patient-year) were reoperated on for degenerated prostheses, with 13 deaths. Twelve patients died without reoperation, and 17 await reoperation for degenerated valves. The rate of structural failure (total, 87 patients) was 21.07% and 3.04% per patient-year for patients less than and older than 20 years, respectively (p less than 0.001). The 6-year actuarial survival for these two groups was 50% and 68%, respectively. However, for patients 20 years old or younger, survival free from degeneration was only 20% at 6 years (p less than 0.001). Bioprostheses have a high failure rate and should not be implanted in young patients or in patients with a life expectancy exceeding 10 years.

This article has been cited by other articles:

				S. Kabbani, H. Jamil, F. Nabhani, A. Hamoud, K. Katan, N. Sabbagh, A. Koudsi, L. Kabbani, and G. Hamed Analysis of 92 mitral pulmonary autograft replacement (Ross II) operations. J. Thorac. Cardiovasc. Surg., October 1, 2007; 134(4): 902 - 908.e7. [Abstract] [Full Text] [PDF]

				S. S. Kabbani, H. Jamil, A. Hammoud, J. A. Hatab, F. Nabhani, R. Hariri, N. Sabbagh, and D. Ross The mitral pulmonary autograft: assessment at midterm Ann. Thorac. Surg., July 1, 2004; 78(1): 60 - 65. [Abstract] [Full Text] [PDF]

				S. Milo, Z. Adler, Y. Bar-El, V. Kertsman, S. Sawaed, A. Lorber, and S. Reisner NO-REACT* ANTICALCIFICATION TISSUE TREATMENT RESULTS WITH STENTLESS HEART VALVES IN TWO ADOLESCENTS J. Thorac. Cardiovasc. Surg., June 1, 1999; 117(6): 1222 - 1223. [Full Text] [PDF]

				C. A. Salles, E. Buffolo, J. C. Andrade, J. H. Palma, R. R.P. Silva, R. Santiago, I. S. Casagrande, and M. C. V. Moreira Mitral valve replacement with glutaraldehyde preserved aortic allografts Eur. J. Cardiothorac. Surg., February 1, 1998; 13(2): 135 - 143. [Abstract] [Full Text] [PDF]

				D. M. Cosgrove, B. W. Lytle, P. C. Taylor, M. T. Camacho, R. W. Stewart, P. M. McCarthy, D. P. Miller, M. R. Piedmonte, and F. D. Loop The Carpentier-Edwards pericardial aortic valve: Ten-year results J. Thorac. Cardiovasc. Surg., September 1, 1995; 110(3): 651 - 662. [Abstract] [Full Text]